25 Sep IXORA-S Study Suggest Taltz May Provide Significantly Greater Clearance of Nail Psoriasis
MedicalResearch.com Interview with:
Lotus Mallbris, M.D., Ph.D.,
Vice president, Immunology Development
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: By exploring creative clinical approaches and patient-centric pathways to more thoroughly address the key aspects of treating these complex conditions, Lilly is bringing innovation forward in hopes of reducing the burden of dermatologic disease for people around the world.
The results of the IXORA-S study suggest that Taltz may provide significantly greater clearance of nail psoriasis than ustekinumab. This is significant because nail lesions are a common feature of psoriasis. It’s often associated with discomfort, which can lead to functional impairment and distress, further supporting the importance of complete clearance.
MedicalResearch.com: Is there anything else you would like to add?
Response: Lilly also evaluated real-world perspectives of people with psoriasis and their treating dermatologists about the benefit of achieving complete versus almost complete skin clearance. In the study, Dermatologic Life Quality Index (DLQI) scores and Work Productivity Loss were significantly lower for complete clear skin patients versus almost clear patients. The results of the real-world study suggest that a goal of completely clear skin can offer substantial quality of life and work productivity benefits over almost clear skin in psoriasis patients, highlighting the significance of complete skin clearance.
In addition, with multiple therapies for atopic dermatitis currently under development, there’s a lack of standardization and validation with the investigator global assessment (IGA) scales. In collaboration with atopic dermatitis experts, academic institutions and other pharmaceutical companies, Lilly presented a study investigating the clinical utility of the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) for the assessment of disease severity, which was conducted in collaboration with atopic dermatitis experts, academic institutions and other pharmaceutical companies. vIGA-AD™ can help harmonize disease severity assessment in future AD clinical trials. The vIGA-AD scale and associated training module are available to investigators and sponsors through the International Eczema Council and Lilly.
Presented at EADV 2018
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on September 27, 2018 by Marie Benz MD FAAD